Brief Report: Enhanced Normalization of CD4/CD8 Ratio with Earlier Antiretroviral Therapy at Primary HIV Infection

Journal of Acquired Immune Deficiency Syndromes

Volumn 73, Issue 1, 2016, Pages 69-73

  Thornhill, John ^a   Inshaw, Jamie ^b   Kaleebu, Pontiano ^c   Cooper, David ^d   Ramjee, Gita ^e   Schechter, Mauro ^f   Tambussi, Giuseppe ^g   Fox, Julie ^h   Samuel, Miriam ^h   Miro, Jose M ⁱ   Weber, Jonathan ^a   Porter, Kholoud ^b   Fidler, Sarah ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c UGANDA VIRUS RESEARCH INSTITUTE   (Uganda)

^d UNIVERSITY OF NEW SOUTH WALES   (Australia)

^e SOUTH AFRICAN MEDICAL RESEARCH COUNCIL   (South Africa)

^f FEDERAL UNIVERSITY OF RIO DE JANEIRO   (Brazil)

^g SAN RAFFAELE HOSPITAL   (Italy)

^h KING'S COLLEGE LONDON   (United Kingdom)

ⁱ UNIVERSITY OF BARCELONA   (Spain)

Author keywords

acute HIV infection; CD4 CD8 ratio; CD4:CD8; early antiretroviral therapy; primary HIV infection; seroconversion

Indexed keywords

ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; NONNUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITOR;

ADULT; ANTIVIRAL THERAPY; ARTICLE; CD4 CD8 RATIO; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE COURSE; FEMALE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; NORMAL VALUE; PRIMARY INFECTION; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SEROCONVERSION; TIME TO TREATMENT; HIV INFECTIONS; IMMUNOLOGY;

ADULT; ANTI-HIV AGENTS; CD4-CD8 RATIO; COHORT STUDIES; DISEASE PROGRESSION; FEMALE; HIV INFECTIONS; HUMANS; MALE;

EID: 84963682415     PISSN: 15254135     EISSN: 10779450     Source Type: Journal    
DOI: 10.1097/QAI.0000000000001013     Document Type: Article

References (38)

1. Fahey JL, Taylor JMG, Detels R, et al. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Engl J Med. 1990;322:166-172.
2. Taylor JM, Fahey JL, Detels R, et al. CD4 percentage, CD4 number, and CD4:CD8 ratio in HIV infection: which to choose and how to use. J Acquir Immune Defic Syndr. 1989;2:114-124.
3. Leung V, Gillis J, Raboud J, et al. Predictors of CD4:CD8 ratio normalization and its effect on Health outcomes in the Era of combination antiretroviral therapy. PLoS One. 2013;8:10.
4. Young J, Psichogiou M, Meyer L, et al. CD4 cell count and the risk of AIDS or death in HIV-Infected adults on combination antiretroviral therapy with a suppressed viral load: a longitudinal cohort study from COHERE. PLoS Med. 2012;9:e1001194.
5. Sabin CA, Phillips AN. Should HIV therapy be started at a CD4 cell count above 350 cells/microl in asymptomatic HIV-1-infected patients? Curr Opin Infect Dis. 2009;22:191-197.
6. Nakagawa F, May M, Phillips A. Life expectancy living with HIV: recent estimates and future implications. Curr Opin Infect Dis. 2013;26:17-25.
7. Emery S, Neuhaus JA, Phillips AN, et al. Major clinical outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the SMART study. J Infect Dis. 2008;197: 1133-1144.
8. Serrano-Villar S, Gutierrez C, Vallejo A, et al. The CD4/CD8 ratio in HIV-infected subjects is independently associated with T-cell activation despite long-term viral suppression. J Infect. 2013;66:57-66.
9. Tinago W, Coghlan E, Macken A, et al. Clinical, immunological and treatment-related factors associated with normalised CD4+/CD8+T-cell ratio: effect of naive and Memory T-cell subsets. PLoS One. 2014;9:9.
10. Zaman MM, Recco RA, Raguthu L, et al. Characteristics of HIV-1-infected patients with CD4: CD8 lymphocyte ratio normalization on antiretroviral therapy. Aids Patient Care STDS. 2000;14:647-649.
11. Badura RAR, Janeiro N, Afonso C, et al. What drives a normal relation between T-CD4 and T-CD8? Paper presented at: Tenth International Congress on Drug Therapy in HIV Infection; 2010; Glasgow, Scotland.
12. Mussini C, Lorenzini P, Cozzi-Lepri A, et al. CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV. 2015;2:e98-e106.
13. Margolick JB, Munoz A, Donnenberg AD, et al. Failure of T-cell homeostasis preceding AIDS in HIV-1 infection. The Multicenter AIDS cohort study. Nat Med. 1995;1:674-680.
14. Frazer IH, Mackay IR, Crapper RM, et al. Immunological abnormalities in asymptomatic homosexual men: correlation with antibody to HTLVIII and sequential changes over two years. Q J Med. 1986;61:921-933.
15. Chun TW, Justement JS, Pandya P, et al. Relationship between the size of the human immunodeficiency virus type 1 (HIV-1) reservoir in peripheral blood CD4+ T cells and CD4+:CD8+ T cell ratios in aviremic HIV-1-infected individuals receiving long-term highly active antiretroviral therapy. J Infect Dis. 2002;185:1672-1676.
16. Riddler S, Aga E, Bosch R, et al. Pre-art HIV-1 RNA as well as ontreatment CD8 count and CD4/CD8 ratio predict residual viremia on ART. Paper presented at: Conference on Retroviruses and Opportunistic Infections; 2014; Boston, M.A.
17. Buggert M, Frederiksen J, Noyan K, et al. Multiparametric bioinformatics distinguish the CD4/CD8 ratio as a Suitable Laboratory predictor of combined T cell pathogenesis in HIV infection. J Immunol. 2014;192: 2099-2108.
18. Mudd JC, Lederman MM. CD8 T cell persistence in treated HIV infection. Curr Opin HIV AIDS. 2014;9:500-505.
19. Lundgren JD, Babiker AG, Gordin F, et al. Initiation of antiretroviral therapy in early asymptomatic HIV infection. N Engl J Med. 2015;373: 795-807.
20. Le T, Wright EJ, Smith DM, et al. Enhanced CD4+ T-cell recovery with earlier HIV-1 antiretroviral therapy. N Engl J Med. 2013;368:218-230.
21. Fidler S, Porter K, Ewings F, et al. Short-course antiretroviral therapy in primary HIV infection. N Engl J Med. 2013;368:207-217.
22. Uk Register Of Hiv Seroconverters Steering Committee. The Uk Register of HIV seroconverters: methods and analytical issues. Epidemiol Infect. 1996;117:305-312.
23. Torti C, Prosperi M, Motta D, et al. Factors influencing the normalization of CD4+ T-cell count, percentage and CD4+/CD8+ T-cell ratio in HIVinfected patients on long-term suppressive antiretroviral therapy. Clin Microbiol Infect. 2012;18:449-458.
24. Serrano-Villar S, Sainz T, Lee SA, et al. HIV-infected individuals with low CD4/CD8 ratio despite effective antiretroviral therapy exhibit altered T cell subsets, heightened CD8+ T cell activation, and increased risk of non-AIDS morbidity and mortality. PLoS Pathog. 2014;10:e1004078.
25. Ndumbi P, Falutz J, Pant pai N, et al. Delay in cART initiation results in persistent immune dysregulation and poor recovery of T-cell phenotype despite a decade of Successful HIV suppression. PLoS One. 2014;9:e94018.
26. Williams I, Churchill D, Anderson J, et al. British HIV Association guidelines for the treatment of HIV-1-positive adults with antiretroviral therapy 2012 (Updated 2013. All changed text is cast in yellow highlight.). HIV Med. 2014;15(suppl 1):1-85.
27. Gunthard HF, Aberg JA, Eron JJ, et al. Antiretroviral treatment of adult HIV infection: 2014 recommendations of the international Antiviral Society-Usa panel. JAMA. 2014;312:410-425.
28. WHO. Consolidated Guidelines on the Use of Antiretroviral Drugs for Treating and Preventing HIV Infection. Available at: http://www.who. int/hiv/pub/guidelines/arv2013/download/en/2013. Accessed September 1, 2015.
29. Doherty M. New directions in the 2015 WHO Consolidated ARV Guidelines. 8th IAS Conference on HIV Pathogenesis, Treatment and Prevention. July 2015. Vancouver, Canada. Presentation SUSA0608. Available at: http://pag.ias2015.org. Accessed August 2015.
30. Sainz TSV, Lee SA, Hunt PW, et al. CMV and HIV: a double hit on the CD4/CD8 ratio. Paper presented at: CROI 2014; 6th March 2014; Boston, M.A.
31. Strindhall J, Skog M, Ernerudh J, et al. The inverted CD4/CD8 ratio and associated parameters in 66-year-old individuals: the Swedish HEXA immune study. Age (Dordr). 2013;35:985-991.
32. Phillips AN, Lee CA, Elford J, et al. More rapid progression to AIDS in older HIV-infected people: the role of CD4+ T-cell counts. J Acquir Immune Defic Syndr. 1991;4:970-975.
33. Cressey TR, Green H, Khoo S, et al. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children. Clin Infect Dis. 2008;46:1601-1608.
34. Kikaire B, Khoo S, Walker AS, et al. Nevirapine clearance from plasma in African adults stopping therapy: a pharmacokinetic substudy. AIDS. 2007;21:733-737.
35. Ho YC, Shan L, Hosmane NN, et al. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell. 2013;155:540-551.
36. Williams JP, Hurst J, Stohr W, et al. HIV-1 DNA predicts disease progression and post-treatment virological control. ELife. 2014;3: e03821.
37. Hurst J, Hoffmann M, Pace M, et al. Immunological biomarkers predict HIV-1 viral rebound after treatment interruption. Nat Commun. 2015; 6:8495.
38. Jain V, Hartogensis W, Bacchetti P, et al. Antiretroviral therapy initiated within 6 months of HIV infection is associated with lower T-cell activation and smaller HIV reservoir size. J Infect Dis. 2013;208:1202-1211.